君实生物 · Junshi Biosciences

Global Presence

Manufacturing

Our Wujiang and Lingang sites connect biologics process development with supply for clinical trials and commercial markets.

Biopharmaceutical manufacturing at Junshi

Manufacturing Sites

The two operating sites have a disclosed fermentation capacity of 46,500 L in total.

Suzhou Wujiang

4,500 L

Fermentation capacity. Completed in 2016, the facility manufactures toripalimab for international commercial supply.

Shanghai Lingang

42,000 L

Phase I fermentation capacity. The site produces commercial medicines and investigational material for clinical studies.

Lingang expansion plan. In its May 2026 disclosure, the company outlined a further 120,000 L of capacity for the Phase II expansion and redevelopment project.

Capabilities & Quality

Process development

Teams develop manufacturing processes, optimize production conditions and support technology transfer.

Clinical and commercial supply

Both sites support manufacturing. Wujiang supplies toripalimab for overseas markets. Lingang also produces clinical trial material.

Quality management

Quality systems govern manufacturing and testing. Lingang obtained GMP certification in May 2022.

Manufacturing site addresses